Share
HERG Screening Market Size, Share, and Analysis, By Type (Gene KCNH2, Mutant KCNH2, and Others), By Ion Channel (Voltage Gated, Ligand Gated, and Others), By Application (Antiarrhythmic, Antipsychotic, Antibiotic, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest of the World) And Regional Forecast 2024-2034
HERG Screening Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 13.7% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 1.7 billion and is projected to reach USD 7.1 billion by the completion of 2034.
HERG screening refers to an essential component in drug development, which serves to evaluate the cardiotoxicity of a compound. The HERG gene includes a potassium ion channel which is crucial for regulating cardiac electrical activity. Certain drugs have the potential to cause fatal ventricular arrhythmias by blocking HERG channels, which causes longer QT intervals on ECGs. HERG screening is an active measure that involves the systematic testing of compounds to assess their impact on HERG channels. This process helps in early identification and elimination of drugs with potential proarrhythmic effects and ensures a safer pharmaceutical development pathway. Consequently, by identifying and reducing the risks associated with HERG inhibition, this screening method contribute in the well-being of patient and minimize cardiovascular complications related to drug usage.
HERG Screening Market is projected to reach USD 7.1 billion over the forecast period, owing to the rising focus on drug safety within the pharmaceutical development sector. The increasing awareness of potential cardiotoxicity risks that are associated with drug compounds is promoting the demand for HERG screening services and technologies. This surge is attributed to the persistent endeavours by pharmaceutical industries to improve drug development methods and adhere to regulatory standards. Additionally, technological innovations in high-throughput screening and automation are significant contributors, which facilitate the effective assessment of compound libraries. Moreover, frequent collaborations between pharmaceutical companies and contract research organizations highlights a strategic change towards outsourcing HERG screening services. This development indicates of a wider industry strategy to improve efficiency while maintaining strict safety protocols. Thus, as the global pharmaceutical ecosystem continues its expansion, HERG screening market will assume an important role in ensuring the safety and efficacy of emerging drug candidates, thereby presenting attractive opportunities for stakeholders in this sector.
Source: Fatpos Global
Based on Type, the HERG Screening Market is segmented into Gene KCNH2, Mutant KCNH2, and Others. The Gene KCNH2 segment will likely dominate the HERG screening market owing to its essential role in the transport of positively charged potassium atoms out of cells. This process is important for the generation and transmission of electrical impulses. Additionally, Gene KCNH2 is responsible for directing the synthesis of potassium channels by providing necessary instructions for their formation. Furthermore, mutations in the KCNH2 gene significantly contribute in the development of cardiac arrhythmias and can even lead to prolonged QT syndrome. Therefore, given the central importance of Gene KCNH2 in regulating the transportation of cellular potassium and its direct impact on cardiac rhythm, Gene KCNH2 will maintain its market dominance. The occurrence of prolonged QT syndrome linked with KCNH2 mutations further highlights the significance of this gene and emphasize its role in shaping the HERG screening market.
By Ion-Channel, HERG Screening Market is divided into Voltage Gated, Ligand Gated, and Others. The voltage-gated ion segment is expected to lead the market due to its crucial role in cellular function. This segment includes Na+, Ca+, and K+ channels, which are integral components of the voltage-gated ion channel family. These channels control open and closed states based on variations in the potential of cell membrane and impacts the vital cellular activities in neurons, heart muscle, and skeletal muscle cells. The accurate control of ion transit across cell membranes by these channels is fundamental for maintaining essential ionic gradients. Additionally, voltage-gated ion channels are extremely important as therapeutic targets for various medical conditions such as epilepsy and neuropathic pain. The increasing adoption of voltage-gated ion channels in the treatment of these disorders has become a major factor for the growth of this market. This attests to the rising importance of these channels in medical applications, which contributes to the growth and dominance of voltage-gated ion segment.
Source: Fatpos Global
Improvements in Technology will Generate Growth Opportunities
Continuous improvements in technology play an essential role in advancing the HERG screening market. High-throughput screening technologies and automated platforms have transformed the environment of drug development, which provided faster and more accurate evaluation of cardiac risks associated with drug candidates. These innovations empower researchers to efficiently evaluate extensive compound libraries, that lead to a significant reduction in time and resources required for screening. Additionally, the incorporation of advanced technologies improves the accuracy of HERG screening methods and also contributes to overall enhancements in drug development workflows. Therefore, this strategic arrangement with regulatory standards ensures compliance and encourage the creation of safer and effective medications, underscoring the significance of technological advancements in the HERG screening market.
Increased Focus on Drug Safety will Lead to Market Expansion
Growing focus on drug safety in the pharmaceutical sector is a significant driving factor for the growth of HERG screening market. Global regulatory agencies are intensifying safety standards and mandating thorough assessments of potential cardiac risks associated with new drug candidates. Thus, pharmaceutical firms are increasingly acknowledging the significance of integrating HERG screening into their preclinical evaluations. This increasing awareness has induced a cultural shift towards active risk management and has encouraged companies to invest in advanced screening methods to ensure the safety of their products. This emphasis aligns with regulatory expectations and has enhanced public health outcomes by eliminating unforeseen cardiovascular complications associated with pharmaceutical use.
Industry Growth Could be Hampered by Cost and Resource Intensiveness
HERG screening has plenty of potential to improve medication safety, but due to its expensive and resource-intensive requirements, it is not yet widely adopted. The implementation and maintenance of essential infrastructure, including specialized laboratory setups and modern equipment, requires substantial financial commitments. The involvement of skilled personnel that are proficient in conducting HERG assays further adds to the overall expenses. This resource-intensive nature presents major difficulties for smaller pharmaceutical companies or research institutions that are operating with limited budgets, which restrict their access to HERG screening capabilities. Therefore, striking a balance between the need for comprehensive safety assessments and the economic practicality of HERG screening is a crucial consideration for stakeholders.
HERG Screening Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America's prominence in the HERG Screening market is due to advanced pharmaceutical industry, strong healthcare infrastructure, and a commitment to research & development. Leading pharmaceutical companies in the region, such as Charles River Laboratories International, Inc. and Covance Inc., are actively integrating HERG screening into their preclinical evaluations, thereby aligning with strict regulatory standards set by the U.S. Food and Drug Administration (FDA). Furthermore, the emphasis on innovation in North America region creates fresh demand for HERG screening technologies. This comprehensive approach highlights the dominance of North America in the HERG Screening market and positions it as a major player in the global landscape.
Source: Fatpos Global
Global pharmaceutical and biotechnology sectors experienced widespread ramifications from the pandemic. Disruptions in supply chains, combined with delays in clinical trials, and a redirection of resources towards COVID-19 research and vaccine development had an indirect effect on the demand for HERG screening services and technologies. The pandemic's impact on drug discovery and safety testing influenced the pace and priorities within the pharmaceutical industry, which shaped the landscape of the HERG screening market. Furthermore, the pandemic encouraged regulatory agencies to adapt to the evolving situation.
|
ATTRIBUTE |
DETAILS |
|
Study Period |
2018-2034 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2034 |
|
Historical Period |
2019-2022 |
|
Growth Rate |
CAGR of 13.7% from 2024-2034 |
|
Unit |
Value (USD Billion) |
|
Segmentation |
Main Segments List |
|
By Type |
|
|
By Ion-Channel |
|
|
By Application |
|
|
By Region |
|
HERG Screening Market size was values at USD 1.7 billion in 2023 and is projected to reach the value of USD 7.1 billion in 2034, exhibiting a CAGR of 13.7% during the forecast period.
The HERG Screening Market involves the assessment of potential cardiac risks associated with drug candidates. It focuses on screening compounds for their effects on HERG channels, crucial for regulating heart rhythm.
Gene KCNH2 segment and the Voltage Gated segment accounted for the largest HERG Screening Market share.
Key players in the HERG Screening Market include Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., Molecular Devices, LLC, Eurofins Discovery, Nanion Technologies GmbH, QPS Holdings, LLC, SB Drug Discovery, Sophion Bioscience A/S, ChanTest Corporation, Cyprotex, Evotec SE, Apredica, Shanghai Medicilon Inc., B'SYS GmbH, Acea Biosciences, Inc., and Other Prominent Players.
Improvements in technology and increased focus on drug safety are the factors driving the HERG screening market.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
